<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691455</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-1053</org_study_id>
    <nct_id>NCT02691455</nct_id>
  </id_info>
  <brief_title>The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)</brief_title>
  <acronym>ASSISTS</acronym>
  <official_title>The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Feldman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outcomes of subjects with uncontrolled glaucoma with a single existing aqueous tube shunt
      implant undergoing a second aqueous shunt to transscleral diode laser cyclophotocoagulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study comparing short- (1 year), mid- (3 years), and long-term (5 years) cumulative
      incidences of failures in participants who undergo a second aqueous shunt (SAS) to those
      cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS) to
      those cumulative incidences of failures in participants who undergo transscleral diode laser
      cyclophotocoagulation (TLC) for eyes with uncontrolled glaucoma with a single existing
      aqueous tube shunt procedure.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare cumulative incidences of failures</measure>
    <time_frame>5 years</time_frame>
    <description>Compare cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS) to those cumulative incidences of failures who undergo transscleral diode laser cyclophotocoagulation (TLC) for eyes with uncontrolled glaucoma with a single existing aqueous shunt implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare cumulative incidences of failures</measure>
    <time_frame>1 year</time_frame>
    <description>Compare cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS) to those cumulative incidences of failures who undergo transscleral diode laser cyclophotocoagulation (TLC) for eyes with uncontrolled glaucoma with a single existing aqueous shunt implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare cumulative incidences of failures</measure>
    <time_frame>3 years</time_frame>
    <description>Compare cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS) to those cumulative incidences of failures who undergo transscleral diode laser cyclophotocoagulation (TLC) for eyes with uncontrolled glaucoma with a single existing aqueous shunt implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of vision-threatening complications</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative incidence of vision-threatening complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of eyes that lose more than two lines of vision</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of eyes that lose more than two lines of vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pain</measure>
    <time_frame>1 week, 1 month</time_frame>
    <description>Assessed by the Universal Pain Assessment Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of visits</measure>
    <time_frame>3 months, 1 year, 5 years</time_frame>
    <description>Total number of visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vision-related quality of life assessed by NEI VFQ-25</measure>
    <time_frame>1 year, 3 years, 5 years</time_frame>
    <description>Changes in vision-related quality of life assessed by National Eye Institute Visual Functioning Questionnaire - 25 (NEI VFQ-25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pain</measure>
    <time_frame>1 week, 1 month</time_frame>
    <description>Assessed by the Universal Pain Assessment Tool</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second Aqueous Shunt
Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transscleral Cyclophotocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transscleral Diode Laser Cyclophotocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt Glaucoma Implant 350-mm2 / BG101-350</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transscleral Diode Laser Cyclophotocoagulation</intervention_name>
    <description>Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.</description>
    <arm_group_label>Transscleral Cyclophotocoagulation</arm_group_label>
    <other_name>Transscleral Diode Laser Cyclophotocoagulation (TLC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed Model FP7 Flexible Plate</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt Glaucoma Implant 250-mm2 / BG103-250</intervention_name>
    <arm_group_label>Second Aqueous Shunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men 18 to 85 years of age

          -  Glaucoma not adequately controlled (IOP &gt;18 mmHg on maximum tolerated topical therapy)
             with a single aqueous shunt (AS).

          -  Best-corrected visual acuity (BCVA) of hand motion (HM) or better in the study eye

        Exclusion Criteria:

          -  Monocular

          -  Presence of more than one AS in the study eye

          -  Previous cyclodestruction in the study eye

          -  Presence of active iris neovascularization in the study eye

          -  Binocular diplopia

          -  Presence of scleral buckle in the study eye

          -  History or scleritis in either eye

          -  History of scleromalacia in the study eye

          -  Insufficient conjunctiva to cover AS in the study eye

          -  IOP cannot be accurately measured with Goldmann applanation, Pneumotonometry, or
             Tono-Pen in the study eye

          -  Presence of silicone oil in the study eye

          -  Presence of retinal detachment in the study eye

          -  Presence of intraocular or orbital tumor affecting the study eye

          -  Need for cataract extraction or concurrent procedure at the time of study treatment,
             except tectonic aqueous shunt revisions for both groups is allowed.

          -  In the opinion of the investigator, should not be enrolled in this study

          -  Unwilling or unable to give consent and satisfy requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Feldman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert Cizik Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego - Shiley Eye Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence and Glaucoma Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Consultants of St. Louis</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers; New Jersey Medical School; IOVS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Institute of Northern NJ, LLC</name>
      <address>
        <city>Rochelle Park</city>
        <state>New Jersey</state>
        <zip>07062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Harkness Eye Institute / Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Kittner Eye Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devers Eye Institute/Legacy Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Eye Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Cizik Eye Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine Eye Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WVU Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <reference>
    <citation>Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of Various Glaucoma Surgeries and Procedures in Medicare Beneficiaries from 1994 to 2012. Ophthalmology. 2015 Aug;122(8):1615-24. doi: 10.1016/j.ophtha.2015.04.015. Epub 2015 Jun 16.</citation>
    <PMID>26092196</PMID>
  </reference>
  <reference>
    <citation>Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012 May;153(5):789-803.e2. doi: 10.1016/j.ajo.2011.10.026. Epub 2012 Jan 15.</citation>
    <PMID>22245458</PMID>
  </reference>
  <reference>
    <citation>Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM; Ahmed Baerveldt Comparison Study Group. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015 Feb;122(2):308-16. doi: 10.1016/j.ophtha.2014.08.043. Epub 2014 Oct 17.</citation>
    <PMID>25439606</PMID>
  </reference>
  <reference>
    <citation>Anand A, Tello C, Sidoti PA, Ritch R, Liebmann JM. Sequential glaucoma implants in refractory glaucoma. Am J Ophthalmol. 2010 Jan;149(1):95-101. doi: 10.1016/j.ajo.2009.07.019. Epub 2009 Oct 17.</citation>
    <PMID>19837382</PMID>
  </reference>
  <reference>
    <citation>Burgoyne JK, WuDunn D, Lakhani V, Cantor LB. Outcomes of sequential tube shunts in complicated glaucoma. Ophthalmology. 2000 Feb;107(2):309-14.</citation>
    <PMID>10690831</PMID>
  </reference>
  <reference>
    <citation>Ness PJ, Khaimi MA, Feldman RM, Tabet R, Sarkisian SR Jr, Skuta GL, Chuang AZ, Mankiewicz KA. Intermediate term safety and efficacy of transscleral cyclophotocoagulation after tube shunt failure. J Glaucoma. 2012 Feb;21(2):83-8. doi: 10.1097/IJG.0b013e31820bd1ce.</citation>
    <PMID>21336148</PMID>
  </reference>
  <reference>
    <citation>Jiménez-Román J, Gil-Carrasco F, Costa VP, Schimiti RB, Lerner F, Santana PR, Vascocellos JP, Castillejos-Chévez A, Turati M, Fabre-Miranda K. Intraocular pressure control after the implantation of a second Ahmed glaucoma valve. Int Ophthalmol. 2016 Jun;36(3):347-53. doi: 10.1007/s10792-015-0125-z. Epub 2015 Sep 3.</citation>
    <PMID>26334729</PMID>
  </reference>
  <reference>
    <citation>Semchyshyn TM, Tsai JC, Joos KM. Supplemental transscleral diode laser cyclophotocoagulation after aqueous shunt placement in refractory glaucoma. Ophthalmology. 2002 Jun;109(6):1078-84.</citation>
    <PMID>12045047</PMID>
  </reference>
  <reference>
    <citation>Smith M, Buys YM, Trope GE. Second Ahmed valve insertion in the same eye. J Glaucoma. 2009 Apr-May;18(4):336-40. doi: 10.1097/IJG.0b013e318182edfb.</citation>
    <PMID>19365202</PMID>
  </reference>
  <reference>
    <citation>Godfrey DG, Krishna R, Greenfield DS, Budenz DL, Gedde SJ, Scott IU. Implantation of second glaucoma drainage devices after failure of primary devices. Ophthalmic Surg Lasers. 2002 Jan-Feb;33(1):37-43.</citation>
    <PMID>11820661</PMID>
  </reference>
  <reference>
    <citation>Ko SJ, Hwang YH, Ahn SI, Kim HK. Surgical Outcomes of Additional Ahmed Glaucoma Valve Implantation in Refractory Glaucoma. J Glaucoma. 2016 Jun;25(6):e620-4. doi: 10.1097/IJG.0000000000000298.</citation>
    <PMID>26091182</PMID>
  </reference>
  <reference>
    <citation>Francis BA, Kawji AS, Vo NT, Dustin L, Chopra V. Endoscopic cyclophotocoagulation (ECP) in the management of uncontrolled glaucoma with prior aqueous tube shunt. J Glaucoma. 2011 Oct;20(8):523-7. doi: 10.1097/IJG.0b013e3181f46337.</citation>
    <PMID>21048513</PMID>
  </reference>
  <reference>
    <citation>Sood S, Beck AD. Cyclophotocoagulation versus sequential tube shunt as a secondary intervention following primary tube shunt failure in pediatric glaucoma. J AAPOS. 2009 Aug;13(4):379-83. doi: 10.1016/j.jaapos.2009.05.006.</citation>
    <PMID>19683190</PMID>
  </reference>
  <reference>
    <citation>Schaefer JL, Levine MA, Martorana G, Koenigsman H, Smith MF, Sherwood MB. Failed glaucoma drainage implant: long-term outcomes of a second glaucoma drainage device versus cyclophotocoagulation. Br J Ophthalmol. 2015 Dec;99(12):1718-24. doi: 10.1136/bjophthalmol-2015-306725. Epub 2015 May 29.</citation>
    <PMID>26024673</PMID>
  </reference>
  <reference>
    <citation>Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005 Sep;24(5):612-37. Review.</citation>
    <PMID>15919228</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>February 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Robert Feldman</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To the American Glaucoma Society members after completion of the study, with an institutional review board (IRB) approved protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

